ERYTHROMYCIN | N050610 | PADDOCK LABORATORIES LLC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | Inova Health Care Services | 140 | 2024-03-08 → 2027-10-01 | |
| Phase 4 | By Invitation | Universitaire Ziekenhuizen KU Leuven | 15 | 2014-03 → 2025-03 | |
| Phase 4 | Recruiting | Centre for Human Drug Research, Netherlands | 30 | 2018-03-20 → 2019-12 | |
| Phase 1/2 | Recruiting | Genmab | 952 | 2022-12-07 → 2027-10 | |
| Phase 1 | Completed | Pfizer | 12 | 2012-06 → 2012-08 | |
| N/A | Completed | Virginia Commonwealth University | 18 | 2013-04 → 2015-06 | |
| Phase 1 | Completed | Adil Bharucha | 30 | 2010-06 → 2013-11 | |
| Phase 4 | Completed | Baqiyatallah Medical Sciences University | — | — | |
| Phase 4 | Completed | University of California, San Francisco | 401 | 2017-10-02 → 2019-11-14 | |
| N/A | Completed | University Hospital, Gasthuisberg | 250 | 2012-11 → 2017-05 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
10 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.